Validation that metabolic tumor volume predicts outcome in head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 5, 2012, Pages 1514-1520

  Tang, Chad ^a   Murphy, James D ^a   Khong, Brian ^a   La, Trang H ^a   Kong, Christina ^b   Fischbein, Nancy J ^b   Colevas, A Dimitrios ^b   Iagaru, Andrei H ^b   Graves, Edward E ^a   Loo Jr , Billy W ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Head and neck cancer; Metabolic tumor volume; Positron emission tomography

Indexed keywords

COMPUTED TOMOGRAPHY; DATA SETS; DEFINITIVE RADIOTHERAPY; DISEASE PROGRESSION; FDG PET; HAZARD RATIO; HEAD-AND-NECK CANCER; HUMAN PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; OVERALL SURVIVAL; PRE-TREATMENT; PROGRESSION FREE SURVIVAL; STANDARDIZED UPTAKE VALUES; TUMOR VOLUMES;

COMPUTERIZED TOMOGRAPHY; DISEASES; METABOLISM; POSITRON EMISSION TOMOGRAPHY;

TUMORS;

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KARNOFSKY PERFORMANCE STATUS; LYMPH NODES; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862120345     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.10.023     Document Type: Article

References (18)

1. J.P. Pignon, A. le Maitre, and E. Maillard Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
2. K.K. Ang, J. Harris, and R. Wheeler Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
3. NCT01084083. Paclitaxel, cisplatin, and cetuximab followed by cetuximab and intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery. http://www.clinicaltrials.gov. Accessed May 2011.
4. T.H. La, E.J. Filion, and B.B. Turnbull Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer Int J Radiat Oncol Biol Phys 74 2009 1335 1341
5. J.D. Murphy, T.H. La, and K. Chu Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer Int J Radiat Oncol Biol Phys 80 2011 514 521
6. C. Tang, F. Kligman, and C.C. Larsen Platelet and endothelial adhesion on fluorosurfactant polymers designed for vascular graft modification J Biomed Mater Res A 88 2009 348 358
7. C.S. Kong, B. Narasihan, and H. Cao The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas Int J Radiat Oncol Biol Phys 74 2009 553 561
8. R.J. Gray A class of k-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
9. D. Rischin, R.J. Young, and R. Fisher Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial J Clin Oncol 28 2010 4142 4148
10. S. Marur, G. D'Souza, and W.H. Westra HPV-associated head and neck cancer: A virus-related cancer epidemic Lancet Oncol 11 2010 781 789
11. B.J. Moeller, V. Rana, and B.A. Cannon Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer J Clin Oncol 27 2009 2509 2515
12. P. Xie, J.B. Yue, and H.X. Zhao Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma J Cancer Res Clin Oncol 136 2010 883 889
13. Hu K, Urdaneta A, Young A, et al. Value of pre-treatment PET and post-treatment pathologic nodal status to predict risk for distant metastasis in N2-3 patients treated with concurrent chemotherapy. Multidisciplinary Head and Neck Cancer Symposium, Chandler, AZ, Feb 25-27,2010.
14. M.E. Daly, Q.T. Le, and A.K. Jain Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx Head Neck 33 2011 103 111
15. M.E. Daly, Q.T. Le, and P.G. Maxim Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: Clinical outcomes and patterns of failure Int J Radiat Oncol Biol Phys 76 2010 1339 1346
16. M.E. Juweid, S. Stroobants, and O.S. Hoekstra Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578
17. R. Murakami, H. Uozumi, and T. Hirai Impact of FDG-PET/CT fused imaging on tumor volume assessment of head-and-neck squamous cell carcinoma: Intermethod and interobserver variations Acta Radiol 49 2008 693 699
18. J.F. Daisne, T. Duprez, and B. Weynand Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen Radiology 233 2004 93 100